Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III adjuvant chemoradiotherapy with tumor bed boost for cervical gastric-type adenocarcinoma
ChiCTR2600121751Phase 3Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of paclitaxel in cervical adenocarcinoma (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: 3-year progression-free survival. Started Apr 2026; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
cervical adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600121751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121751.